Intravenous and aerosolized polymyxins are being used increasingly, especially in the critical care setting, for treating patients with infections due to multidrug-resistant Gram-negative bacteria, mainly Acinetobacter baumannii and Pseudomonas aeruginosa. Recent literature suggests that intravenous colistin and polymyxin B have acceptable effectiveness for the treatment of patients with bacteremia, as well as infections of various systems and organs, including pneumonia, bacteremia, skin and soft tissue, and urinary tract infections. Although data from recent studies have suggested that the toxicity of intravenous polymyxins is probably less than reported in the older literature, caution should be taken to monitor the renal function of patients who receive these antibiotics.
The lack of development of new antimicrobial agents, in combination with the emergence of Gram-negative bacteria that produce extended spectrum β-lactamases and metallo-β-lactamases, represent major health threats that affect patient outcomes, particularly in the intensive care unit. Strains of Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae that exhibit resistance to almost all available antibiotics, except polymyxins, have emerged as common causes of hospital acquired infections in critically ill patients. [1] [2] [3] Polymyxins have been recently considered as last therapeutic options for the treatment of patients with these types of infections. In addition, the administration of polymyxins intrathecally or intraventricularly has been evaluated recently as a potential alternative intervention for the treatment of multidrug-resistant Gram-negative central nervous system infections. Although the level of evidence to support the use of polymyxins by these modes of administration is low, the reported data are promising. [4] [5] [6] History, Mechanism of Action and Spectrum of Activity Polymyxins are a group of polypeptide cationic antibiotics. 7 Major components of this class of antimicrobial agents that have been used in clinical practice represent colistin (polymyxin E) and polymyxin B. Colistin and polymyxin B were discovered from different species of Bacillus polymyxa in the 1940s and were extensively used parenterally for approximately two decades, after which they were gradually withdrawn from clinical practice owing to reports of toxicity. [8] [9] [10] [11] [12] Specifically, several studies that assessed the safety of parenteral polymyxins reported frequent development of renal and neurological adverse effects. 13, 14 In addition, numerous case reports published in the 1960s and 1970s associated the administration of polymyxins with the development of acute renal failure. [15] [16] [17] Polymyxins consist of a cyclic decapeptide molecule, which is positively charged and linked to a fatty acid chain that has been found to be either 6-methyl-octanic acid or 6-methyl-eptanoic acid. The main difference between the molecules of polymyxin B and colistin is in the amino acid components. 7 Colistin consists of D-leucine, L-threonine and L-αγ-diaminobutyric acid, while polymyxin B contains D-phenylalanine instead of D-leucine. 7 The cationic molecules of polymyxin B and colistin compete and displace Ca 2+ and Mg 2+ ions which normally stabilize the lipopolysaccharide molecule of the outer membrane of Gram-negative bacteria. This outer membrane of Gram-negative bacteria. This displacement causes local disturbance of the cell membrane, increased cell permeability, leakage of the cell content, cell lysis and death. 18, 19 In addition, a remarkable property of polymyxins is the ability to neutralize lipopolysaccharide molecules of Gram-negative bacteria, thus inducing anti-endotoxin activities. 20 In patients with sepsis, continuous hemodialysis therapy with polymyxin-B immobilized fiber has been correlated with improvement of the survival rates. 21 24 Dosage adjustments are recommended for patients with mild to moderate renal dysfunction. Specifically, when the serum creatinine level is 1.3-1.5 mg/dl, 1.6-2.5 mg/dl or ≥2.6 mg/dl, the recommended dosage of intravenous colistin for serious infections is 2 million IU every 12 hours, 24 hours or 36 hours, respectively. In the United Kingdom, a dosing regimen of 4-6 mg/kg (50,000-75,000 IU/kg) of colistimethate sodium per day in 3 divided doses is recommended for adults and children with normal renal function and body weight ≤60 kg, and 240-480 mg (3-6 million IU) per day in 3 divided doses for those with body weight >60 kg. This formulation, which is manufactured by Alpharma A/S (Copenhagen, Denmark) and distributed by Forest Laboratories (Kent, United Kingdom) contains 80 mg of colistimethate sodium (1 mg of colistimethate sodium is equal to 12,500 IU). 25 To avoid confusion regarding dosing of colistin, it is preferable to use a dosing system based on International Units (IU). Pure colistin base has a potency of 30,000 IU/mg. The dosage of intravenous polymyxin B recommended by the manufacturer is 1.5-2.5 mg/kg/day (15,000-25,000 IU/kg/day), divided into 2 equal doses for adults and children older than 2 years with normal renal function. One milligram of polymyxin B is equal to 10,000 IU. 26 Recommendations for dosage adjustment of polymyxin B in the presence of renal impairment have not been well established. For both regimens, there are no dosage adjustments for patients with liver failure. It should be noted that neurotoxicity, including neuromuscular blockade and apnea, has been observed with high doses of colistimethate sodium administered intravenously, and it more commonly presents in patients with renal dysfunction when the dosage is not adjusted.
The dosage of aerosolized colistimethate sodium recommended in the United Kingdom is 40 mg (500,000 IU) every 12 hours for patients with body weight ≤40 kg, and 80 mg (1 million IU) every 12 hours for patients with a body weight >40 kg. For recurrent pulmonary infections, the dosage can be increased to 160 mg (2 million IU) every 8 hours. 27 The precise pharmacokinetic-pharmacodynamic properties of polymyxin B and colistimethate sodium have not been completely clarified, and most of the available literature was published approximately three decades ago. However, both polymyxins are poorly absorbed by the gastrointestinal tract following oral administration and are eliminated by the renal route. No hepatic excretion of polymyxin B and colistimethate sodium has been reported in humans. 28 Both polymyxins have rapid concentration dependent bactericidal activity against Gram-negative pathogens 29 and exhibit considerable post-antibiotic effects at high concentrations. 28, 30 
Intravenous Polymyxins in Critically Ill Patients
No well-designed, randomized controlled trials (phase II or III trials) have been conducted to comprehensively evaluate the effectiveness and safety of polymyxins for the treatment of Gram-negative bacterial infections and to elucidate their clinical indications. However, the need for their use in patients with infections caused by polymyxin-only susceptible microorganisms or with infections where the available antimicrobial therapeutic options have failed, has led to the accumulation of valuable experience regarding their usefulness. Table 1 (pages 140-142) summarizes recently published studies that assessed the effectiveness and safety of parenteral polymyxin B and colistimethate sodium for the treatment of critically ill patients with multidrug-resistant Gram-negative bacterial infections. Both medications have been used parenterally in cases of pneumonia, bacteremia, urinary tract infections, surgical site infections, abdominal infections, skin and central nervous system infections. Most recently published studies included severely ill patients with Acute Physiology and Chronic Health Evaluation II (APACHE II) scores ranging from 13 to 26 who suffered from infections caused by multidrug-resistant or polymyxin-only-susceptible Gram-negative bacteria. The observed frequency of clinical cure among patients in these studies was promising. However, a major limitation observed in most of these studies is that combinations of colistimethate sodium and polymyxin B with other antimicrobial agents were used due to the severity of the infections in the intensive care Falagas Polymyxins for treatment of infection unit. Thus, definite statements regarding the effectiveness of intravenous polymyxins as monotherapy cannot be made. [31] [32] [33] In a comparative observational study of intravenous colistimethate sodium versus intravenous meropenem for the treatment of intensive care unit patients with Acinetobacter baumannii ventilator-associated pneumonia, the observed outcomes, including in-hospital mortality, ventilator-associated pneumonia-related mortality and clinical cure, were comparable. 34 
Inhaled Polymyxins in Critically Ill Patients
There is no extensive experience with the use of aerosolized polymyxins for the treatment of critically ill patients with respiratory tract infections caused by multidrug-resistant Gram-negative bacteria. On the contrary, their value in preventing and treating infections due to Pseudomonas aeruginosa in patients with cystic fibrosis has been thoroughly established. [35] [36] [37] It is worth noting that the necessity to improve the outcome among patients with pneumonia due to multidrug-resistant bacteria has led to the use of alternative methods for administration of polymyxins. Most of the experience using aerosolized polymyxins is with colistin and is likely due to the fact that polymyxin B can lead more frequently than colistimethate sodium to release of histamine during nebulization and thus, bronchoconstriction. 38, 39 
Toxicity
The nephrotoxicity of polymyxins has been the major vexation limiting their clinical use. However, recent data, mainly from cases series, suggest that the use of polymyxins is relatively safe provided that recommended dosages are used, renal function is closely monitored and other potential nephrotoxic agents are avoided. The D-amino acid and fatty acid molecules of the structure of polymyxins have been associated with the development of nephrotoxicity, and the suggested mechanism resembles their mechanism of action. [43] [44] [45] In an experimental model, colistin was bound to the apical membrane of the urothelium only when the membrane potential was cell interior negative and increased the transepithelial conductance of the urinary bladder epithelium. In addition, the magnitude of the increase in conductance was dependent on the concentration of colistin and on the voltage of the membrane. The presence of calcium and magnesium decreased the colistin-induced conductance. Moreover, long-term exposure of the membrane at high concentrations of colistin resulted in incomplete return of the transepithelial conductance to normal values after the removal of colistin, suggesting that prolonged exposure to high concentrations of colistin may be associated with toxic renal effects. 46 Additionally, the use of polymyxins has been associated with the experience of several neurotoxic events, including dizziness, muscle weakness, facial and peripheral paresthesia, vertigo, confusion, ataxia and neuromuscular blockade, which can lead to respiratory failure or apnea. However, recent studies in critically ill patients are not consistent with the frequency of polymyxin-related neurotoxic events reported in the earlier literature. 2, 34 Treatment with aerosolized colistin may also be complicated with bronchoconstriction and chest tightness. 36 However, treatment with aerosolized β2-agonists before the initiation of aerosolized colistin could prevent the development of bronchoconstriction.
Conclusion
In conclusion, intravenous and aerosolized polymyxins should be considered for the treatment of critically ill patients with multidrug-resistant Gram-negative bacterial infections. Further research focusing on the appropriate dosage, clinical indications and safety profile of polymyxins is urgently needed. Meanwhile, strict use of polymyxins by clinicians worldwide is required to prevent the rapid development and dissemination of pandrug-resistant Gram-negative bacteria. 1 Falagas et al. 
